Mylan Laboratories (MYL) Levothyroxine Sodium Tablets USP Approved as Generic Equivalent to Levothroid
More News related to FRX
- Ironwood Pharma and Forest Labs (FRX) Announces Positive Top-Line Results for Linaclotide in Two Phase 3's
- Ironwood and Forest Announce Positive Linaclotide Results from Two Pivotal Phase 3 Trials in Patients with Chronic Constipation
- Forest Laboratories, Inc. and Gedeon Richter Announce Positive Results from a Phase IIb Study of Cariprazine for the Treatment of Schizophrenia
- Trading Review for Discovery Laboratories Inc. Issued by Beacon Equity
- Deutsche Bank Upgrades Freeport-McMoRan (FCX) to Buy; More Positive on Stock After 2 Strong Quarters
More News related to MYL
- Mylan's President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
- Mylan's Spanish Business Named Best Generic Pharmaceuticals Company in Spain by Elsevier
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
- Mylan Receives FDA Approval for Generic Version of Prevacid(R) Through its Subsidiary Matrix Laboratories
- Mylan Labs (MYL) Tops Q3 EPS by 5c, Guides Higher
Mylan Laboratories Inc. (NYSE: MYL) announced that the U.S. Food and Drug Administration (FDA) has granted the company approval to market its currently approved Levothyroxine Sodium Tablets, USP as a bioequivalent and, therefore, therapeutically equivalent product to Levothroid Tablets (manufactured by Lloyd Pharmaceuticals for Forest Laboratories Inc. (NYSE: FRX)).
Total U.S. sales for all Levothyroxine brands and generic equivalents were approximately $1 billion for the 12-month period ended Sept. 30, 2006, according to data from IMS Health.
Related Categories
FDAStocks Mentioned
+0.46Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
